Growth Hormone Biotech Ascendis Raises $108M In IPO

Law360, New York (January 28, 2015, 2:43 PM EST) -- Growth hormone treatment developer Ascendis Pharma A/S raised $108 million in its initial public offering on Wednesday by selling 6 million shares at $18 apiece, marking the latest in a flurry of biotech IPOs scheduled for this week.

The Danish drug developer priced at the high end of its range, and the company said in a statement Wednesday that it expects to net roughly $96.4 million in proceeds from the $108 million offering. The proceeds are pegged to go toward further research into developing a treatment...
To view the full article, register now.